Addus HomeCare (NASDAQ:ADUS) Reports Q2 CY2026 In Line With Expectations

Addus HomeCare (NASDAQ: ADUS) reported Q2 CY2026 results. Revenue rose 8% year on year to $377.4 million, matching Wall Street expectations. Non-GAAP adjusted EPS was $1.73, up from $1.49 a year earlier and 1.9% above consensus. Analysts expect full-year EPS to rise from $6.68 to $7.20.

Original reporting
Published Aug 3, 2026, 10:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 10:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Addus HomeCare (NASDAQ:ADUS) Reports Q2 CY2026 In Line With Expectations — source image
Decision brief

The 30-second read

$ADUSNeutralMed
01

Why it matters

Q2 results were described as in line on revenue but slightly ahead on adjusted EPS, with margins stable; the market reaction was negative and the forward revenue growth outlook was projected to decelerate.

02

Market read

Traders can use the reported revenue/EPS and the stated deceleration in expected revenue growth to reassess near-term valuation and earnings trajectory.

03

What to watch

Average billable patients rose to 51,097 while revenue grew slower, implying pricing pressure; traders may focus on whether that trend reverses in subsequent quarters.

Relevance 7/10Novelty 6/10Timing: after-hours/next-session reaction to Q2 results (stock down 2.6% immediately following)

Background

Addus HomeCare serves about 66,000 clients across 22 states, focused on dual-eligible Medicare and Medicaid beneficiaries.

Company-level read

Ticker impact

$ADUSNeutralMedium confidence
Context

Addus HomeCare reported Q2 CY2026 revenue of $377.4M (+8% YoY) and adjusted EPS of $1.73, beating consensus by 1.9%.

Expected impact

Near-term volatility likely persists; follow-through depends on whether investors re-rate the decelerating revenue outlook and patient mix.

Evidence & confidence

The article provides hard earnings datapoints (revenue, EPS, margin stability) plus a same-article price reaction (down 2.6%), and notes analyst expectations for revenue growth to slow to 5.4% over 12 months.

Market effects

Home healthcare demand appears resilient but the cited 12-month revenue growth deceleration may temper sector multiple expectations.

No specific regional read-through beyond the company’s 22-state footprint.

Limited, as this is company-specific earnings with no cross-border catalyst described.

Counterpoint

The EPS beat and stable adjusted operating margin (11.5%) could indicate quality earnings; the selloff may reflect positioning rather than deteriorating fundamentals.

Key entities

  • Addus HomeCare

    Home healthcare provider reporting Q2 CY2026 revenue, adjusted EPS, margins, and patient metrics.

  • Wall Street consensus

    Analysts’ revenue and EPS expectations referenced for the beat/in-line assessment.

Related articles

$DTMedAI 8/10

Dynatrace Springs on Q1 Figures

Dynatrace (NYSE: DT) reported Q1 FY2027 results for the quarter ended June 30, 2026. Total ARR was $2,136 million, up 17%. Total revenue rose to $555 million, up 16%. Subscription revenue was $530 million. GAAP operating income was $71 million and non-GAAP $162 million. CEO Rick McConnell cited 41% organic net new ARR growth and accelerating TTM growth.

$DBXMed

Dropbox Shares Decline Despite Earnings Beat as Revenue Growth Disappoints

Dropbox (DBX) shares fell about 5% premarket to around $32.80 after Q2 2026 results. The company reported adjusted EPS of $0.75 vs $0.74 expected and revenue of $631.5M vs about $627M, but revenue rose only 0.9% year over year. Non-GAAP operating margin improved to 39.7%. Paying users reached 18.19M. William Blair upgraded to Market Perform, while consensus remains Sell.

$HLMedAI 8/10

Hecla Mining Q2 Earnings Call Highlights

Hecla Mining reported Q2 financial and operating updates. The company ended the quarter with $483 million cash, about $472 million net cash, and an essentially undrawn $225 million revolver. It projected 2026 free cash flow of about $500 million at $50 silver and $3,500 gold, and raised Greens Creek silver guidance to 8.0-8.3 million ounces. Production guidance was adjusted for Lucky Friday and Keno Hill.

$RCELHighAI 9/10

Avita Medical Shares Surge After Record Second-Quarter Performance

Avita Medical (NASDAQ:RCEL) shares rose about 21.7% in premarket after it reported record Q2 results. Revenue was $21.7M, up 18% YoY and about 8% above estimates. Adjusted loss per share narrowed to $0.25 vs $0.30 expected. Full-year 2026 revenue guidance raised to $86M-$89M and cash-flow breakeven targeted for Q4 2026. BTIG upgraded to Buy with a $7.00 target.

$NETHighAI 9/10

Cloudflare shares jump after forecast raise on higher AI-driven spending

Cloudflare shares rose about 16% premarket after the company raised its full-year outlook, citing higher enterprise spending on AI infrastructure. Cloudflare now forecasts revenue of $2.86B to $2.87B and adjusted EPS of $1.25 to $1.26. Reuters also notes strong cloud growth at Amazon and rising developer additions.